Cdk2-null Mice Are Resistant to ErbB-2-induced Mammary Tumorigenesis

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2011 May 3

PMID 21532884

Citations 16

Authors

Dipankar Ray

Yasuhisa Terao

Konstantin Christov

Philipp Kaldis

Hiroaki Kiyokawa

Affiliations

Soon will be listed here.

Abstract

The concept of targeting G(1) cyclin-dependent kinases (CDKs) in breast cancer treatments is supported by the fact that the genetic ablation of Cdk4 had minimal impacts on normal cell proliferation in majority of cell types, resulting in near-normal mouse development, whereas such loss of Cdk4 completely abrogated ErbB-2/neu-induced mammary tumorigenesis in mice. In most human breast cancer tissues, another G(1)-regulatory CDK, CDK2, is also hyperactivated by various mechanisms and is believed to be an important therapeutic target. In this report, we provide genetic evidence that CDK2 is essential for proliferation and oncogenesis of murine mammary epithelial cells. We observed that 87% of Cdk2-null mice were protected from ErbB-2-induced mammary tumorigenesis. Mouse embryonic fibroblasts isolated from Cdk2-null mouse showed resistance to various oncogene-induced transformation. Previously, we have reported that hemizygous loss of Cdc25A, the major activator of CDK2, can also protect mice from ErbB-2-induced mammary tumorigenesis [Cancer Res (2007) 67(14): 6605-11]. Thus, we propose that CDC25A-CDK2 pathway is critical for the oncogenic action of ErbB-2 in mammary epithelial cells, in a manner similar to Cyclin D1/CDK4 pathway.

Citing Articles

Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception.

Giarolla J, Holdaway K, Nazari M, Aiad L, Sarkar B, Georg G Future Med Chem. 2025; 17(5):607-627.

PMID: 40034037 PMC: 11901406. DOI: 10.1080/17568919.2025.2463868.

Atypical cell cycle regulation promotes mammary stem cell expansion during mammary development and tumourigenesis.

Fifield B, Vusich J, Haberfellner E, Andrechek E, Porter L Breast Cancer Res. 2024; 26(1):106.

PMID: 38943151 PMC: 11212383. DOI: 10.1186/s13058-024-01862-1.

CCNA2 facilitates epithelial-to-mesenchymal transition via the integrin αvβ3 signaling in NSCLC.

Ruan J, Zhou H, Yang L, Wang L, Jiang Z, Wang S Int J Clin Exp Pathol. 2020; 10(8):8324-8333.

PMID: 31966683 PMC: 6965382.

Cell cycle proteins as promising targets in cancer therapy.

Otto T, Sicinski P Nat Rev Cancer. 2017; 17(2):93-115.

PMID: 28127048 PMC: 5345933. DOI: 10.1038/nrc.2016.138.

Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.

Law M, Corsino P, Narayan S, Law B Mol Pharmacol. 2015; 88(5):846-52.

PMID: 26018905 PMC: 4613943. DOI: 10.1124/mol.115.099325.

References

Ray D, Terao Y, Fuhrken P, Ma Z, DeMayo F, Christov K . Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 2007; 67(3):984-91. DOI: 10.1158/0008-5472.CAN-06-3927. View

Fantl V, Edwards P, Steel J, Vonderhaar B, Dickson C . Impaired mammary gland development in Cyl-1(-/-) mice during pregnancy and lactation is epithelial cell autonomous. Dev Biol. 1999; 212(1):1-11. DOI: 10.1006/dbio.1999.9329. View

Takano Y, Takenaka H, Kato Y, Masuda M, Mikami T, Saegusa M . Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity. J Cancer Res Clin Oncol. 1999; 125(8-9):505-12. DOI: 10.1007/s004320050309. View

Macias E, Miliani de Marval P, De Siervi A, Conti C, Senderowicz A, Rodriguez-Puebla M . CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development. Am J Pathol. 2008; 173(2):526-35. PMC: 2475789. DOI: 10.2353/ajpath.2008.071124. View

Ray D, Terao Y, Nimbalkar D, Hirai H, Osmundson E, Zou X . Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res. 2007; 67(14):6605-11. DOI: 10.1158/0008-5472.CAN-06-4815. View

Macias E, Kim Y, Miliani de Marval P, Klein-Szanto A, Rodriguez-Puebla M . Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis. Cancer Res. 2007; 67(20):9713-20. PMC: 2859620. DOI: 10.1158/0008-5472.CAN-07-2119. View

Tetsu O, McCormick F . Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003; 3(3):233-45. DOI: 10.1016/s1535-6108(03)00053-9. View

Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G . A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010; 18(1):63-73. DOI: 10.1016/j.ccr.2010.05.025. View

Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y . Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006; 9(1):23-32. DOI: 10.1016/j.ccr.2005.12.012. View

10.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

11.

Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P . Cdk2 knockout mice are viable. Curr Biol. 2003; 13(20):1775-85. DOI: 10.1016/j.cub.2003.09.024. View

12.

Ray D, Kiyokawa H . CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008; 68(5):1251-3. DOI: 10.1158/0008-5472.CAN-07-5983. View

13.

Samady L, Dennis J, Budhram-Mahadeo V, Latchman D . Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor. Cancer Biol Ther. 2004; 3(3):317-23. View

14.

Muller W, Sinn E, Pattengale P, Wallace R, Leder P . Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988; 54(1):105-15. DOI: 10.1016/0092-8674(88)90184-5. View

15.

Yu Q, Geng Y, Sicinski P . Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001; 411(6841):1017-21. DOI: 10.1038/35082500. View

16.

Deshpande A, Sicinski P, Hinds P . Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005; 24(17):2909-15. DOI: 10.1038/sj.onc.1208618. View

17.

Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R . Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet. 2003; 35(1):25-31. DOI: 10.1038/ng1232. View

18.

Kiyokawa H, Ray D . In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med Chem. 2008; 8(8):832-6. PMC: 2753225. DOI: 10.2174/187152008786847693. View

19.

Vandenbosch R, Borgs L, Beukelaers P, Foidart A, Nguyen L, Moonen G . CDK2 is dispensable for adult hippocampal neurogenesis. Cell Cycle. 2007; 6(24):3065-9. DOI: 10.4161/cc.6.24.5048. View

20.

Cangi M, Cukor B, Soung P, Signoretti S, Moreira Jr G, Ranashinge M . Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000; 106(6):753-61. PMC: 381390. DOI: 10.1172/JCI9174. View